ADRB2 and rheumatoid arthritis: β2-AR agonists in RA are reported to downregulated proinflammatory cytokine production and increase anti-inflammatory cytokines, as well as decreasing T cell infiltration to the synovium (Lubahn et al., 2014; Bellinger et al., 2021).